{"id":458478,"date":"2021-03-16T08:03:12","date_gmt":"2021-03-16T12:03:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=458478"},"modified":"2021-03-16T08:03:12","modified_gmt":"2021-03-16T12:03:12","slug":"acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/","title":{"rendered":"Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates"},"content":{"rendered":"<h2>\nPrograms receiving funding include those developing company\u2019s proprietary cryopreserved NK and gamma delta T-cell candidates<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">SAN MATEO, Calif., March  16, 2021  (GLOBE NEWSWIRE) &#8212; Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced\u00a0the closing of its $47 million Series B financing. The funding will be used to advance the company\u2019s lead off-the-shelf natural killer (NK) cell therapy candidate, ACE1702, through clinical development in solid tumors, and to advance its preclinical NK and gamma delta T cell therapy pipeline into the clinic. Acepodia anticipates completing IND-enabling studies for two additional pipeline products in 2021.<\/p>\n<p align=\"justify\">The funding round was supported by new U.S. institutional investors, including Ridgeback Capital Investments, 8VC, and DEFTA Partners, and the Taiwan-based institutional investor-CDIB Capital Healthcare. Acepodia\u2019s Series A investors also participated.<\/p>\n<p align=\"justify\">\u201cThis second capital raise for Acepodia represents a strong vote of confidence by our investors in our highly differentiated approach to cell therapy, particularly with NK cells, and in the Company\u2019s potential to provide superior treatment options for patients with cancer,\u201d said Sonny Hsiao, Ph.D., founder and chief executive officer of Acepodia. \u201cAccessible and effective allogeneic, off-the-shelf cell therapies will be an important part of next generation cancer therapy. With our discipline and capital efficiency, we are well-positioned to execute on our corporate objectives, including the continued clinical development of these therapies, including our lead candidate, ACE1702 for the treatment of solid tumors, and execution of future clinical trial initiations for our promising preclinical portfolio of NK and NK-like gamma delta T cell therapy candidates.\u201d<\/p>\n<p align=\"justify\">Wayne Holman, M.D., Chief Executive Officer and Founder of Ridgeback Capital, added, \u201cWe are excited to participate in this financing for Acepodia as we are believers in the foundational evidence suggesting cell therapies should play a significant role in the future of cancer therapy. We believe the prior success of Acepodia\u2019s leadership group in cell therapies, and the unique Antibody-Cell Conjugation (ACC)\u00a0technology when applied to allogeneic\u00a0off-the-shelf cryopreserved\u00a0NK cells could lead to enhanced and differentiated results.\u201d<\/p>\n<p align=\"justify\">Acepodia\u2019s technology enables development of cell therapies with improved tumor engagement and targeting through optimized cell receptor selection, and seamless conjugation with antibody therapies. Utilizing its proprietary, patent-protected Antibody-Cell Conjugation (ACC) technology, Acepodia is able to directly conjugate and arm NK or gamma delta T cells with validated anti-tumor antibodies for cell therapies, a design which has demonstrated the ability to overcome traditionally resilient tumor defenses in preclinical trials. The company is currently conducting an ongoing Phase 1 clinical trial of ACE1702, the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors.<\/p>\n<p>\n        <strong>About Acepodia<\/strong>\n      <\/p>\n<p align=\"justify\">Acepodia is a privately held biotechnology company focused on eradicating cancers of all types with potent and targeted first-in-class cell therapies. The company\u2019s next generation allogeneic natural killer (NK) cell therapies are based on a proprietary NK cell line (oNK) that has been selected for its potent anti-tumor activity. This cell line is further enhanced by the company\u2019s proprietary ACC (Antibody-Cell Conjugation) technology that links tumor-targeting antibodies to the surface proteins of oNK cells to direct and maximize tumor cell killing. The company\u2019s lead product candidate, ACE1702, is an antibody-conjugated NK cell therapy in clinical development at multiple U.S. cancer centers for the treatment of HER2-expressing solid tumors. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rDXDhOsEDadMQ9BPJqoCV06QQGrxnoTmrqHQ76afi469HdA1iK-aUItU0C8mM9gBamq9ow4vw2M9h5md67oHb0a07oXbS_F5jP3_J3Wvvft7KCOTwuYyTRfZT77lgo_bvRtUbkgiTBofS5d9-azafohJzKtGlfxZJxdXANbiZx1JTknwsOjkATnXsLi_U50PTxa0Ey2AwRBEqfKNDlbUQHneesJNbAB-0-u5d8LAZsDIPH-XluIS0m_zDFLB4Z9ys-UNFNFPlYXhCLu7A9KH6w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>https:\/\/www.acepodia.com<\/strong><\/a>.<\/p>\n<p>\n        <strong>Acepodia Contact<\/strong><br \/>\n        <br \/>Spike Lo, Senior Director of Business Development<br \/>Acepodia<br \/>886 (2) 2697-6100<br \/><strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JHB1VokPJLn_TTjeAOUuuyZylftoIXx6oyRn4JPYhRLWi_d_yoWPLhHulaYxH7dnv_dYENx2Ks557rf1pHNskMTPLIuZ4zi03hKgV5BNd84=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">spike@acepodiabio.com<\/a><\/strong><\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Sylvia Wheeler<br \/>Wheelhouse Life Science Advisors<br \/><strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5rjs6RvTDzguYkl2qhjc5YA-GzgoNfRp9_mFfXI3cOrCjXte01uWxLG3vr2GCgx448rwopMaeKAhiGxp8sqBQhU6btc2rCqx3Teioe00hRK8KODWefRSCn7CXOMSyzOL\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">swheeler@wheelhouselsa.com<\/a><\/strong><\/p>\n<p><strong>Media Contact<\/strong><br \/>Michael Tattory\u00a0<br \/>LifeSci Communications<br \/>1 (646) 751-4362<br \/><strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7sz0MF_gCnOU0O8NnoOkQMDBRbhKuRoRSRSccYUBIjvhG66er5mqU59ebdg4KaVrlB8PdzP3EF67hvR8YVWCFig85LoRyLrUgDasihD_imA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mtattory@lifescicomms.com<\/a><\/strong><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDI1OCM0MDY0NjE1IzUwMDA3MDA1Mw==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f82a22ca-6dc4-4ec1-a580-a0d35fb88f9a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Programs receiving funding include those developing company\u2019s proprietary cryopreserved NK and gamma delta T-cell candidates SAN MATEO, Calif., March 16, 2021 (GLOBE NEWSWIRE) &#8212; Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced\u00a0the closing of its $47 million Series B financing. The funding will be used to advance the company\u2019s lead off-the-shelf natural killer (NK) cell therapy candidate, ACE1702, through clinical development in solid tumors, and to advance its preclinical NK and gamma delta T cell therapy pipeline into the clinic. Acepodia anticipates completing IND-enabling studies for two additional pipeline products in 2021. The funding round was supported by new U.S. institutional investors, including Ridgeback Capital Investments, 8VC, and DEFTA Partners, and the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-458478","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Programs receiving funding include those developing company\u2019s proprietary cryopreserved NK and gamma delta T-cell candidates SAN MATEO, Calif., March 16, 2021 (GLOBE NEWSWIRE) &#8212; Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced\u00a0the closing of its $47 million Series B financing. The funding will be used to advance the company\u2019s lead off-the-shelf natural killer (NK) cell therapy candidate, ACE1702, through clinical development in solid tumors, and to advance its preclinical NK and gamma delta T cell therapy pipeline into the clinic. Acepodia anticipates completing IND-enabling studies for two additional pipeline products in 2021. The funding round was supported by new U.S. institutional investors, including Ridgeback Capital Investments, 8VC, and DEFTA Partners, and the &hellip; Continue reading &quot;Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-16T12:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDI1OCM0MDY0NjE1IzUwMDA3MDA1Mw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates\",\"datePublished\":\"2021-03-16T12:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\\\/\"},\"wordCount\":608,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDI1OCM0MDY0NjE1IzUwMDA3MDA1Mw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\\\/\",\"name\":\"Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDI1OCM0MDY0NjE1IzUwMDA3MDA1Mw==\",\"datePublished\":\"2021-03-16T12:03:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDI1OCM0MDY0NjE1IzUwMDA3MDA1Mw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDI1OCM0MDY0NjE1IzUwMDA3MDA1Mw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/","og_locale":"en_US","og_type":"article","og_title":"Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates - Market Newsdesk","og_description":"Programs receiving funding include those developing company\u2019s proprietary cryopreserved NK and gamma delta T-cell candidates SAN MATEO, Calif., March 16, 2021 (GLOBE NEWSWIRE) &#8212; Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced\u00a0the closing of its $47 million Series B financing. The funding will be used to advance the company\u2019s lead off-the-shelf natural killer (NK) cell therapy candidate, ACE1702, through clinical development in solid tumors, and to advance its preclinical NK and gamma delta T cell therapy pipeline into the clinic. Acepodia anticipates completing IND-enabling studies for two additional pipeline products in 2021. The funding round was supported by new U.S. institutional investors, including Ridgeback Capital Investments, 8VC, and DEFTA Partners, and the &hellip; Continue reading \"Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-16T12:03:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDI1OCM0MDY0NjE1IzUwMDA3MDA1Mw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates","datePublished":"2021-03-16T12:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/"},"wordCount":608,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDI1OCM0MDY0NjE1IzUwMDA3MDA1Mw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/","name":"Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDI1OCM0MDY0NjE1IzUwMDA3MDA1Mw==","datePublished":"2021-03-16T12:03:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDI1OCM0MDY0NjE1IzUwMDA3MDA1Mw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDI1OCM0MDY0NjE1IzUwMDA3MDA1Mw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acepodia-completes-47-million-series-b-financing-to-advance-pipeline-of-allogeneic-cell-therapy-candidates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=458478"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458478\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=458478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=458478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=458478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}